Daniella Beckman served as our Chief Financial Officer from September 2019 to April 2026 and served as our interim Chief Financial Officer from October 2016 to August 2019. Prior to joining Tango, she provided consulting and interim chief financial officer services for early-stage biotechnology companies from November 2015 to September 2019. Previously, Ms. Beckman was the Chief Financial Officer of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from June 2011 until it was acquired by Merck & Co., Inc., a pharmaceutical company, in August 2014. Ms. Beckman currently serves on the board of directors of Upstream Biopharma (NASDAQ: UPB), a biotechnology company developing treatments for inflammatory diseases (since October 2024) and Vor Biopharma Inc. (NASDAQ: VOR), a cell therapies company (since July 2020). Previously, Ms. Beckman served on the board of directors of Blueprint Medicines Corporation (NASDAQ: BPMC), a global precision therapy company, from December 2021 until it was acquired by Sanofi in July 2025, Translate Bio, Inc., a clinical-stage mRNA therapeutics company, from October 2017 to September 2021, and 5:01 Acquisition Corp., a special purpose acquisition company, from October 2020 October 2022. Ms. Beckman holds a B.S. in business administration-accounting from Boston University.